Cancer
Malignant Uterine Corpus Neoplasm
CI-CAN-00008020Explore in graph →
Top-level411 active trials4 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00008020Explore in graph →
Clinical trials
1,571 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03586661 | Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02755844 | Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients(ENDOLA) | completed | Phase 1 / Phase 2 | 35 | Hospices Civils de LyonOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06846099 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 | completed | Phase 1 | 69 | Risen (Suzhou) Pharma Tech Co., Ltd.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03738228 | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03325634 | Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer | completed | Phase 1 | 15 | University of Colorado, DenverOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | completed | Phase 1 | 89 | Tempest TherapeuticsINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06949124 | A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03748186 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | completed | Phase 1 | 136 | Sutro Biopharma, Inc.INDUSTRY | 2 | Aug 20, 2025 | clinicaltrials |
| NCT06969664 | A Trial of SHR7280 in Healthy Subjects | completed | Phase 1 | 16 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 149 | Incyte CorporationINDUSTRY | 3 | Aug 12, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT01226316 | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules | completed | Phase 1 | 285 | AstraZenecaINDUSTRY | 10 | Jun 29, 2025 | clinicaltrials |
| NCT04811196 | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | completed | Phase 1 | 56 | University Health Network, TorontoOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT03508570 | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT02922764 | A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | completed | Phase 1 | 146 | Inspirna, Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03552471 | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 1 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03667716 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | completed | Phase 1 | 121 | Compugen LtdINDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT02630823 | MK-3475 Immunotherapy in Endometrial Carcinoma | completed | Phase 1 | 10 | Washington University School of MedicineOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT02164461 | Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer | completed | Phase 1 | 12 | Advaxis, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT04823065 | 4FMFES-PET Imaging of Endometrial and Ovarian Cancers | completed | Phase 1 / Phase 2 | 53 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT00020267 | Vaccine Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT04474184 | Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates | completed | Phase 1 | 33 | Mayo ClinicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05986266 | Evaluating Efficacy of Intravenous Carbetocin Versus Intramyometrial Injection of Adrenaline in Reducing Blood Loss | completed | Phase 1 | 62 | EgymedicalpediaINDUSTRY | 1 | Oct 17, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT01686256 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer | completed | Phase 1 | 12 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04177693 | Pharmacokinetics and Hepatic Safety of EGCG | completed | Phase 1 | 39 | Yale UniversityOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03366480 | A Study to Assess the Efficacy and Safety of ABTL0812(Endolung) | completed | Phase 1 / Phase 2 | 103 | Ability Pharmaceuticals SLINDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02788708 | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | completed | Phase 1 | 26 | Floor BackesOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT02977195 | First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors(NP137) | completed | Phase 1 | 70 | Centre Leon BerardOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02914470 | Carboplatin-cyclophosphamide Combined With Atezolizumab(PROLOG) | completed | Phase 1 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT02058550 | Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy | completed | Phase 1 | 72 | Stanford UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT02269293 | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | completed | Phase 1 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT01065662 | AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | completed | Phase 1 | 11 | Susana M. Campos, MDOTHER | 1 | Apr 21, 2021 | clinicaltrials |
Data updated 15 days agoSource updated Sep 14, 2026source: clinicaltrials